Gastroesophageal Junction Adenocarcinoma Clinical Trials in Ghent
4 recruitingGhent, Belgium
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled284 locationsNCT06764875
Recruiting
Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Esophageal CancerGastric CancerGastroesophageal Junction Adenocarcinoma
AstraZeneca2,130 enrolled230 locationsNCT07431281
Recruiting
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company257 enrolled76 locationsNCT05993234
Recruiting
Phase 2
Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer
Gastric Cancer Adenocarcinoma MetastaticGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Universitaire Ziekenhuizen KU Leuven100 enrolled6 locationsNCT06962137